Cochrane Reviews on COVID-19 by the READ-It team

Cochrane Reviews: COVID-19

0

Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID‐19 in people with SARS‐CoV‐2

The authors of this review assessed the accuracy of routine blood‐based laboratory tests to predict mortality and deterioration to severe or critical (from mild or moderate) COVID‐19 in people with SARS‐CoV‐2.

Cochrane Systematic Review: NEW

Favipiravir for treating COVID‐19

The authors of this new review assessed the effects of favipiravir compared to no treatment, supportive treatment, or other experimental antiviral treatment in people with acute COVID‐19.

Cochrane Systematic Review: NEW

Update: Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19

The combination of nirmatrelvir with ritonavir (Paxlovid®) is a new medicine developed to treat infection with the SARS‐CoV‐2 virus and aims to avoid severe COVID‐19 in people without symptoms, or those with mild symptoms. This review update assesses the efficacy and safety of nirmatrelvir/ritonavir plus standard of care (SoC) compared to SoC with or without placebo, or any other intervention for treating COVID-19 or preventing SARS-CoV-2 infection.

Cochrane Systematic Review: UPDATE

Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition

In this review the authors examine the theory that amyloid fibrin(ogen) particles (sometimes called “microclots”) are a feature of post-COVID-19 condition and investigate whether there is evidence that plasmapheresis may be an appropriate treatment to remove these particles

Cochrane Systematic Review: NEW